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OutcomesAbstract Background: High-grade osteosarcoma is a primary malignant bone tumour
mainly affecting children and young adults. The European and American Osteosarcoma Study
(EURAMOS)-1 is a collaboration of four study groups aiming to improve outcomes of this
rare disease by facilitating randomised controlled trials.
Methods: Patients eligible for EURAMOS-1 were aged 40 years with M0 or M1 skeletal
high-grade osteosarcoma in which case complete surgical resection at all sites was deemed
to be possible. A three-drug combination with methotrexate, doxorubicin and cisplatin was
defined as standard chemotherapy, and between April 2005 and June 2011, 2260 patients were
registered. We report survival outcomes and prognostic factors in the full cohort of registered
patients.
Results: For all registered patients at a median follow-up of 54 months (interquartile range: 38
e73) from biopsy, 3-year and 5-year event-free survival were 59% (95% confidence interval [CI]:
57e61%) and 54% (95% CI: 52e56%), respectively. Multivariate analyses showed that the most
adverse factors at diagnosis were pulmonarymetastases (hazard ratio [HR]Z 2.34, 95%CI: 1.95
e2.81), non-pulmonary metastases (HR Z 1.94, 95% CI: 1.38e2.73) or an axial skeleton
tumour site (HR Z 1.53, 95% CI: 1.10e2.13). The histological subtypes telangiectatic
(HR Z 0.52, 95% CI: 0.33e0.80) and unspecified conventional (HR Z 0.67, 95% CI: 0.52
e0.88) were associated with a favourable prognosis compared with chondroblastic subtype.
The 3-year and 5-year overall survival from biopsy were 79% (95% CI: 77e81%) and 71%
(95% CI: 68e73%), respectively. For patients with localised disease at presentation and in com-
plete remission after surgery, having a poor histological response was associated with worse
S. Smeland et al. / European Journal of Cancer 109 (2019) 36e5038outcome after surgery (HRZ 2.13, 95% CI: 1.76e2.58). In radically operated patients, there
was no good evidence that axial tumour site was associated with worse outcome.
Conclusions: In conclusion, data from >2000 patients registered to EURAMOS-1 demon-
strated survival rates in concordance with institution- or group-level osteosarcoma trials.
Further efforts are required to drive improvements for patients who can be identified to be at
higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to
the large numbers of patients registered, it sheds light on some additional factors to consider.
ª 2018 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction Of the 2260 registered patients for EURAMOS-1,Osteosarcoma is a malignant bone tumour mainly
affecting children and young adults. Although osteo-
sarcoma is the most common primary malignant bone
cancer, it is a rare disease and has an annual incidence of
3e4 patients per million. The introduction of multi-
agent chemotherapy several decades ago improved 5-
year event-free survival in localised high-grade osteo-
sarcoma from less than 20% to around 60%. Since then,
there have been few evidence-based improvements
introduced shown to improve survival [1e4]. The Eu-
ropean and American Osteosarcoma Study (EUR-
AMOS) collaboration, initiated by four internationally
recognised study groups, was formed to improve out-
comes in osteosarcoma by facilitating the conduct of
randomised controlled trials (RCTs) [5]. These groups
were the Children’s Oncology Group (COG), Cooper-
ative German-Austrian-Swiss Osteosarcoma Study
Group (COSS), European Osteosarcoma Intergroup
(EOI) and Scandinavian Sarcoma Group (SSG).
The EURAMOS-1 trial was a risk-stratified randi-
mised controlled trial, investigating treatment optimi-
sation on the basis of histological response to pre-
operative chemotherapy. Patients eligible for
EURAMOS-1 were aged 40 years at diagnosis with
localised or metastatic skeletal osteosarcoma in which
case complete surgical resection at all sites was deemed
to be possible. The extensive international collaboration
enabled more rapid accrual than any trial groups could
have achieved alone; from April 2005 to June 2011, 2260
patients were registered (enrolled) to the protocol [6].
The EURAMOS-1 collaboration agreed on a stan-
dard of care for osteosarcoma chemotherapy, in which
there had been various approaches used. Accordingly,
the three-drug combination with methotrexate, doxo-
rubicin and cisplatin following the previous COG trial
was defined as standard chemotherapy [7,8]. Thus, the
study cohort represents a large number of patients uni-
formly treated according to the same protocol.
The key adverse prognostic factors at presentation for
survival in osteosarcoma are presence ofmetastases, large
tumour volume and non-extremity (axial) site of the pri-
mary tumour. After surgical resection, response to pre-
operative chemotherapy and achievement of surgical
remission status are prognostically important [9e14].1334 (59%) joined one of the two randomisations [6].
The results of the trial have been previously reported:
No evidence was found that either research treatment
improved event-free survival, the primary outcome
measure [15,16]. The aim of these further analyses is to
report outcomes for the whole cohort of eligible regis-
tered patients, as timed from diagnostic biopsy. We
consider the prognostic impact of factors measured at
diagnosis and the impact of response to pre-operative
chemotherapy in patients with initially localised dis-
ease, timed from surgery.2. Methods
2.1. Patient selection
The EURAMOS-1 protocol contains two open-label
randomised phase III comparisons for patients with
high-grade osteosarcoma, split by good and poor histo-
logical response to pre-operative chemotherapy,
embedded within one overall patient cohort including all
those registered/enrolled in the trial. The trial structure,
eligibility criteria and patient assessments have been
described previously [5,6]. Patients aged 40 years with
newly diagnosed osteosarcoma could be registered within
30 days after the diagnostic biopsy. Diagnostic biopsies
were examined by an institutional pathologist and
reviewed by each study group’s reference pathologist.
Patients with high-grade localised or metastatic, extrem-
ity or axial osteosarcoma deemed to be resectable by their
treating team were potentially eligible pending specific
criteria. These included adequate performance status;
cardiac, hearing, bone marrow, liver and renal function;
no history of chemotherapy for previous malignancy and
no prior treatment for osteosarcoma. Regulatory
approval, ethics approval and consent were obtained ac-
cording to national requirements before registration.
Registration was preferred before treatment started but
could be done up to 30 days afterwards.
All patients were planned for the same pre-operative
therapy for 10 weeks consisting of 120 mg/m2 of
cisplatin and 75 mg/m2 of doxorubicin (weeks 1 and 6)
followed by 12 g/m2 of high-dose methotrexate (weeks 4,
5, 9 and 10). A subset of consenting patients meeting
Fig. 1. Flow diagram describing patient cohorts included in the ‘registration cohort’ and the ‘M0-CSR’ groups for analysis. CT, computed
tomography; EFS, event-free survival; IQR, interquartile range; EURAMOS-1, European and American Osteosarcoma Study-1.
S. Smeland et al. / European Journal of Cancer 109 (2019) 36e50 39further eligibility criteria were randomised post-
operatively based on histological response to pre-
operative chemotherapy; overall, 1334 of 2260 (59%)
registered patients were randomised [6].
The aim of the present analysis was to report patient
outcomes in two key populations: from biopsy, the full
‘registration cohort’, including all registered patients and
excluding any ineligible patients, i.e. those who could be
included in the primary end-point analysis; and from
surgery, the ‘M0-CSR’ subgroup, which was the subset of
the ‘registration cohort’ without baseline metastases and
who achieved complete surgical remission (CSR). Surgi-
cal remission and margins were taken as reported by the
surgeon and pathologist, respectively. We also present
outcome data by metastatic status for patients in the
‘registration cohort’. Details are given in Fig. 1.
We required measures to consistently define non-
metastatic (M0) and metastatic (M1) disease in patients
across the four trials groups. The COSS, EOI and SSG
categorised metastases as ‘no’, ‘possible’ and ‘yes’,
whereas COG used only ‘no’ and ‘yes’. To reflect this
difference, we grouped together patients with ‘no’ and‘possible’ metastases as M0 patients, distinct from M1
patients with confirmed metastases by imaging criteria.
Patients registered with ‘possible’ metastases, who later
record a first event of ‘progression of existing metasta-
ses’ rather than ‘new metastases’, were retrospectively
reclassified as M1 patients at registration because this
ensured that the reporting of progression events was
consistent with patient data at registration; the site must
already have made this decision.
The ‘M0-CSR’ group of patients primarily includes
patients for whom surgical remission or macroscopic
clearance was explicitly reported on the case report form
by the surgeon. However, one or both of these data
items were missing for some patients, mostly patients
who were registered but not randomised for whom the
protocol permitted a reduced burden of form comple-
tion. If one of these items was reported and the other
was missing, the patient was included in the ‘M0-CSR’
group, and providing this information was consistent
with the disease status on the first, timely follow-up
form. If both data items were missing, the patient was
included in the ‘M0-CSR’ group only if the first post-
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remission within 1 year of the surgery date. Patients
were excluded from the ‘M0-CSR’ group if they had
reported an event-free survival (EFS) event before
surgery.
2.2. Outcome measures
The primary outcome measure was EFS, defined as the
time to first event (local recurrence, new metastases, pro-
gression of existing metastases, second malignancy, death
or a combination of those events) or censoring at last
contact. The first event was changed to ‘local progression’
where sites reported ‘local recurrence’ before or without
surgery (this applied to 62 patients). Overall survival was
defined as the time to death or censoring at last contact.
The start time for assessing EFS and survival varies ac-
cording to the analysis: EFS and survival were timed from
the date of diagnostic biopsy for the ‘registration cohort’
and from the date of surgery of the primary tumour (i.e. a
landmark approach) for the ‘M0-CSR cohort’.
2.3. Sample size
The sample size calculation for the original trial was
based on the number required for each of the two
separate, post-operative randomisations: 567 good
response and 693 poor response patients (N Z 1260
total). These, in turn, were driven by the number of EFS
events required for the design parameters (as mentioned
previously). To randomise 1260 patients, it was initially
planned to register around 1400 patients, but because
the randomisation rate was lower than that anticipated,
the sample size for registration was increased to around
2000 registrations. Therefore, the size of the registered
but not randomised patients was substantially larger
here than originally envisaged.
Detailed data on surgery and post-operative chemo-
therapy were not collected for patients who were regis-
tered to the trial but who were not randomised because
our main focus was outcomes in randomised compari-
sons. Follow-up was expected for all registered patients
according to the previously described schedules.
2.4. Statistical analyses
Survival curves were estimated using the KaplaneMeier
method; Cox multivariate models, stratified by study
group (COG, COSS, EOI and SSG), were applied. For
all patients, the following variables were included in the
multivariate models: tumour site and location within
bone (proximal femur/humerus, other limb site or axial
skeleton), pulmonary and non-pulmonary metastases
status at registration, gender, pathological fracture at
diagnosis, age, relative tumour volume (<1/3 or 1/3 of
the involved bone), histological response to surgery,
surgical margins as reported by the pathologist (wide/radical, marginal or intralesional) and World Health
Organisation (WHO) classification of sarcoma. Con-
ventional osteosarcomas were split into three groups
after central review: osteoblastic, chondroblastic and
other. Three age groups were defined according to
Collins et al.: child (male: 0e12 years; female: 0e11
years), adolescent (male: 13e17 years; female: 12e16
years) and adult (male: 18 or older; female: age 17 years
or older) [17]. Relative tumour size was the most
commonly missing data item. To address this, we
applied multiple imputations, creating 20 data sets with
imputed tumour size data to cope with missingness of
almost 20% of patients [18]. There was no evidence of a
difference in survival with either previously reported
research treatment; no analyses here are broken by
allocated randomised treatment.3. Results
3.1. Baseline characteristics
Overall, 2260 patients from 17 countries and 325 hos-
pital sites were registered between April 2005 and June
2011 [6]. Seventy-four of these registered patients were
either ineligible according to the trial eligibility criteria
or unable to be included in the primary outcome anal-
ysis: 36 were ineligible after central pathology review
(diagnosis other than high-grade skeletal osteosarcoma);
26 were registered later than 30 days after diagnostic
biopsy; 8 did not start chemotherapy within 30 days
after diagnostic biopsy and the remaining 4 patients
were ineligible for other reasons. The remaining 2186
registered patients formed the ‘registration cohort’. In
this cohort, median age at biopsy was 14 years (inter-
quartile range [IQR]: 11e17), 59% (1285/2186) were
male, 93% (1997/2138) had conventional osteosarcoma
and 17% (362/2172) had metastases (Table 1). The pri-
mary tumour site was axial skeleton in 5% (106/2172),
proximal femur or humerus in 13% (282/2172) and other
limb site in 82% (1784/2172) of patients (Table 1).3.2. Outcomes from diagnosis (‘registration cohort’:
N Z 2186)
The ‘registration cohort’ patients had a median follow-
up of 54 months (IQR: 38-73) from diagnostic biopsy,
and 45% (974/2186) of patients reported an EFS event.
Three-year EFS from biopsy was 59% (95% confidence
interval [CI] 57e61%), and 5-year EFS was 54% (95%
CI: 52e56%).
The breakdown of types of first event for the 974
‘registration cohort’ patients reporting at least one EFS
event is shown in Table 2.
Note that the 41 patients in Table 2 with death as the
first event without a previously reported progression
event are a subset of the overall total of 621 deaths
Table 1
Characteristics at registration for all ‘registration cohort’ patients, split by metastatic status at registration (N Z 2186).
Patient characteristic M0a at registration M1 at registration Metastases
status at
registration not
known
Total
N % N % N % N %
Age at registrationb
Child 536 30 115 32 6 43 657 30
Adolescent 900 50 168 46 7 50 1075 49
Adult 374 21 79 22 1 7 454 21
Gender
Male 1050 58 230 64 5 36 1285 59
Female 760 42 132 36 9 64 901 41
Site of the tumour
Proximal femur/humerus 227 13 55 15 0 0 282 13
Other limb site 1489 82 295 82 0 0 1784 82
Axial skeleton 94 5 12 3 0 0 106 5
Missing 0 0 0 0 14 100 14 1
Location on the bone
Proximal 712 39 144 40 1 7 857 39
Diaphysis 73 4 19 5 0 0 92 4
Distal 917 51 184 51 0 0 1101 50
Not long bone, n/a 103 6 12 3 0 0 115 5
Missing 5 0 3 1 13 93 21 1
WHO classification of sarcoma at diagnostic biopsy
Conventional: chondroblastic 303 17 39 11 1 7 343 16
Conventional: osteoblastic 1051 58 246 68 8 57 1305 60
Conventional: other 298 16 52 14 5 36 355 16
Telangiectatic 84 5 11 3 0 0 95 4
Small cell 9 1 2 1 0 0 11 1
High-grade surface 25 1 2 1 0 0 27 1
Missing 40 2 10 3 0 0 50 2
Relative tumour volume
Small (<1/3 of involved bone) 848 47 110 30 1 7 959 44
Large (1/3 of involved bone) 638 35 177 49 0 0 815 37
Missing 324 18 75 21 13 93 412 19
Pathological fracture at diagnosis
No 1594 88 308 85 1 7 1903 87
Yes 213 12 54 15 0 0 267 12
Missing 3 0 0 0 13 93 16 1
Surgical margins achievedc
Wide/Radical 1357 75 257 71 13 93 1627 74
Marginal 218 21 34 9 0 0 252 12
Intralesional 23 1 3 1 0 0 26 1
Missing 212 12 68 19 1 7 281 13
Duration of symptoms (weeks)
Median (IQR) 8 8 e 8
Minemax 0e312 0e67 e 0e312
N 1596 324 1d 1921
Total 1810 100 362 100 14 100 2186 100
IQR, interquartile range; WHO, World Health Organisation.
a includes possible metastases.
b age groups defined according to Collins et al.: child (0e12 for males and 0e11 for females), adolescent (13e17 for males and 12e16 for
females) and adult (18 for males and 17 for females).
c as reported by the pathologist.
d data not presented because duration of symptoms is known for only one patient in this group.
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621 deaths, 84% (524/621) of these were attributed to
osteosarcoma; 3% (16/621) to treatment or during
therapy (10 within a year of registration; 6 subsequently)
and 6% (36/621) to other causes, including second ma-
lignancy. The cause of death is not reported for theremaining 7% (45/621). Three-year survival from biopsy
was 79% (95% CI: 77e81%), and 5-year survival was
71% (95% CI: 68e73%) (Fig. 2A).
For multivariable analyses, 243 of 2186 patients were
excluded due to missing data in multiple variables. Out
of 412 patients with missing tumour size data, size was
Table 2
Summary of types of first event, as reported for the 974 ‘registration
cohort’ patients in whom an EFS was reported.
Type of event N %
New metastases 521 53
Combination of events 144 15
New metastases/progression of existing
metastases
58 40
Local recurrence/new metastases 52 36
Local recurrence/new metastases/progression
of existing metastases
13 9
Other or unknown combination 21 15
Progression of existing metastatic disease 89 9
Local progression 74 8
Local recurrence 70 7
Death without any previously reported
progression
41 4
Cause of death attributed to
osteosarcoma/treatmenta
32 78
Other cause of death 9 22
Secondary malignancy 26 3
Unknown event type 9 1
Total 974 100
a Or implicitly attributed to osteosarcoma/treatment as death
occurred during therapy.
Fig. 2. KaplaneMeier plots for event-free survival and overall surviva
patients with localised disease at registration (M0).M0 group includes
‘registration cohort’ patients with metastatic disease at registration (M
at the time of surgery is smaller for EFS than for OS because some pa
overall survival.
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of EFS with 1867 patients from the ‘registration cohort’
recording 762 EFS events (Table 3), poorer EFS was
associated with having pulmonary metastases
(HR Z 2.34, 95% CI: 1.95e2.81) or non-pulmonary
metastases (HR Z 1.94, 95% CI: 1.38e2.73) at diag-
nosis, compared to having no metastases; having an
axial skeleton tumour site (HR Z 1.53, 95% CI:
1.10e2.13) or proximal femur/humerus tumour site
(HR Z 1.50, 95% CI: 1.22e1.84) compared to other
limb site; being adult (HR Z 1.32, 95% CI: 1.07e1.63)
or adolescent (HR Z 1.25, 95% CI: 1.05e1.48)
compared to being a child; being male compared to fe-
male (HRZ 1.20, 95% CI: 1.03e1.39) and having large
relative tumour volume compared to small (HRZ 1.29,
95% CI: 1.09e1.51). Improved EFS was associated with
telangiectatic (HR Z 0.52, 95% CI: 0.33e0.80), high-
grade surface (HR 0.44, 95% CI: 0.19e0.99) and con-
ventional unspecified subtype (HR Z 0.67, 95% CI:
0.52e0.88) classifications, compared to chondroblastic.
A model excluding the imputed tumour size data for 336l. (A) Full ‘registration cohort’. (B) Subset of ‘registration cohort’
patients with no metastases and possible metastases. (C) Subset of
1). (D) ‘M0-CSR’ group, *Note that the number of patients at risk
tients had EFS event before surgery. EFS, event-free survival; OS,
Table 3
Cox model for event-free survival (timed from diagnostic biopsy) for all ‘registration cohort’ patients, N Z 1867.
Characteristic N EFS events Adjusted HR
(95% CI)
p-value Overall p-value
Pulmonary metastases
No metastasesa 1633 607 1.00 n/a <0.001
Metastases 234 155 2.34 (1.95e2.81) <0.001
Other metastases
No metastases 1809 724 1.00 n/a <0.001
Metastases 58 38 1.94 (1.38e2.73) <0.001
Site of the tumour
Other limb site 1562 596 1.00 n/a <0.001
Proximal femur/humerus 234 124 1.50 (1.22e1.84) <0.001
Axial skeleton 71 42 1.53 (1.10e2.13) 0.011
WHO classification of sarcoma at diagnosis
Conventional: chondroblastic 300 144 1.00 n/a 0.002
Conventional: osteoblastic 1154 484 0.85 (0.71e1.03) 0.101
Conventional: other 293 99 0.67 (0.52e0.88) 0.003
Telangiectatic 86 24 0.52 (0.33e0.80) 0.003
Small cell 10 5 1.48 (0.60e3.64) 0.389
High-grade surface 24 6 0.44 (0.19e0.99) 0.047
Age
Child 557 201 1.00 n/a 0.015
Adolescent 921 388 1.25 (1.05e1.48) 0.013
Adult 389 173 1.32 (1.07e1.63) 0.008
Gender
Female 761 288 1.00 n/a 0.017
Male 1106 474 1.20 (1.03e1.39) 0.017
Relative tumour volumeb
Small (<1/3 of involved bone) 851 307 1.00 n/a 0.002
Large (1/3 of involved bone) 680 333 1.29 (1.09e1.51) 0.002
Pathological fracture at diagnosis
No 1645 669 1.00 n/a 0.966
Yes 222 93 1.00 (0.80e1.26) 0.966
Surgical margins achievedc
Wide/Radical 1593 636 1.00 n/a 0.262
Marginal 249 110 1.03 (0.82e1.30) 0.797
Intralesional 25 16 1.54 (0.92e2.59) 0.102
CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.
a includes possible metastases.
b 336 missing values imputed.
c as reported by the pathologist.
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imputed data included. The CIs were broader in this
model (due to fewer patients), but the interpretation is
the same (Appendix Table 1).
An additional model with the same patient cohort
using overall survival as the outcome demonstrated a
similar prognosis impact from each of these factors
(Appendix Table 2). The CIs around the estimates are
broader for the OS model than those for the EFS model
because there are fewer deaths than EFS events.
3.3. Outcomes from diagnosis by baseline metastases
(‘registration cohort’: N Z 2186)
Of the ‘registration cohort’, 1810 of 2186 (83%) of the
patients were registered with localised disease (M0), 362
of 2186 (17%) were M1 and metastasis status was not
reported for 14 of 2186 (<1%). There were 711 EFSevents reported in the M0 patient subset (Table 1). For
these M0 patients, 3-year EFS from biopsy was 65%
(95% CI: 63e67%), and 5-year EFS from biopsy was
60% (95% CI: 57e62%). With a median follow-up of 56
months, 422 deaths were reported in these patients with
localised disease, with 3-year survival from biopsy 84%
(95% CI: 82e86%) and 5-year survival from biopsy 76%
(95% CI: 74e78%) (Fig. 2B).
For the 362 of 2186 (17%) M1 patients at presenta-
tion, the median follow-up was 47 months, and 254
patients reported an EFS event. Three-year EFS from
biopsy was 32% (95% CI: 27e37%), and 5-year EFS
from biopsy was 28% (95% CI: 23e33%). A total of 194
deaths were reported; 3-year survival from biopsy was
56% (95% CI: 50e61%), and 5-year survival from biopsy
was 45% (95% CI: 39e50%) (Fig. 2C).
The risk of an EFS event was highest around the
second year after diagnosis for both M1 and M0
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the same lower level for both M1 and M0 patients four
years after diagnosis, but risk continues (Fig. 3).3.4. Outcomes from surgery (‘M0-CSR’ group,
N Z 1549)
Of the patients registered with localised disease (M0),
1549 of 1810 (86%) M0 patients were considered to have
evidence of CSR (‘M0-CSR’ group). These patients had
a median follow-up time from surgery of 57 months
(IQR: 39-74) with 545 patients reporting an EFS event;
3-year EFS from surgery was 70% (95% CI: 67e72%),
and 5-year EFS from surgery was 64% (95% CI:
61e66%). There were 308 deaths reported; 3-year sur-
vival from surgery was 88% (95% CI: 86e89%), and 5-
year survival from surgery was 79% (95% CI: 77e81%).
In the ‘M0-CSR’ group, 1395 of 1549 (90%) patients
were included in the multivariate model of EFS (Table
4); missing tumour volume was imputed for 240 of
these patients. Poor histological response to chemo-
therapy was strongly associated with poorer EFS than a
good histological response (HR Z 2.13, 95% CI:
1.76e2.58). Poorer EFS was also associated with
tumour site on the proximal femur or humerus than
other limb site (HR Z 1.38, 95% CI: 1.06e1.80) and
being adult (HR Z 1.53, 95% CI: 1.17e1.99) or
adolescent (HR Z 1.43, 95% CI: 1.14e1.79) compared
to being a child. There was some limited evidence that
having a conventional unspecified subtype osteosarcoma
classification as opposed to chondroblastic wasFig. 3. Hazard of event-free survival (EFS) from diagnostic biopsy fo
registration. Note: non-COG patients categorised at registration as hav
area shows 95% CI around estimates. CI, confidence interval; COG, Cassociated with improved EFS (HR Z 0.71, 95% CI:
0.52e0.96); however, pathology overall was not a sta-
tistically significant variable in the model (P Z 0.157;
Table 4). Appendix Table 3 shows survival for the ‘M0-
CSR’ group; the interpretation of the prognostic factors
is similar to the EFS model for this patient group.4. Discussion
The EURAMOS-1 is the largest osteosarcoma trial
performed to date. Of the 2260 patients registered to the
protocol, 2186 were eligible for this cohort analysis. The
large number of patients and the broad eligibility criteria
of patients with operable osteosarcoma, which
include patients with axial or metastatic disease,
extend the relevance of our findings compared to most
other osteosarcoma trials [7,8,13,19,20].
A three-drug MAP combination, based on COG’s
INT-0133 trial, was agreed upon as standard therapy for
the EURAMOS-1 [7,8]. Here, the 5-year EFS and sur-
vival from diagnosis for all eligible patients were 54%
and 71%, respectively. For patients with localised dis-
ease, the 5-year EFS (60%) and survival (76%) were
comparable to previously reported osteosarcoma studies
in patients with tumours entirely or mostly located in
extremities, conducted by the founding members of the
EURAMOS-1 [7,8,13,20]. Other study groups using
different 3- or 4-drug schedules from these same active
drugs have reported similar results as the EURAMOS-1
[19,21]. The patients with metastatic disease recruited to
this trial were selected on the condition that the diseaser all ‘registration cohort’ patients, plotted by metastatic status at
ing ‘possible’ metastases are included in the M0 category. Shaded
hildren’s Oncology Group.
Table 4
Cox model for event-free survival (timed from surgery) for all ‘M0-CSR’ patients (N Z 1395).
Characteristic N EFS events Adjusted HR (95% CI) p-value Overall p-value
Site of the tumour
Other limb site 1175 382 1.00 n/a 0.039
Proximal femur/humerus 166 72 1.38 (1.06e1.80) 0.018
Axial skeleton 54 27 1.29 (0.86e1.95) 0.214
WHO classification of sarcoma at diagnosis
Conventional: chondroblastic 240 103 1.00 n/a 0.157
Conventional: osteoblastic 830 284 0.91 (0.72e1.14) 0.408
Conventional: other 230 69 0.71 (0.52e0.96) 0.029
Telangiectatic 69 18 0.71 (0.42e1.20) 0.199
Small cell 6 2 0.79 (0.19e3.20) 0.737
High-grade surface 20 5 0.45 (0.18e1.12) 0.086
Age
Child 409 110 1.00 n/a 0.003
Adolescent 689 250 1.43 (1.14e1.79) 0.002
Adult 297 121 1.53 (1.17e1.99) 0.002
Gender
Female 586 189 1.00 n/a 0.071
Male 809 292 1.19 (0.99e1.43) 0.071
Relative tumour volumea
Small (<1/3 of the involved bone) 679 214 1.00 n/a 0.046
Large (1/3 of the involved bone) 476 197 1.24 (1.00e1.52) 0.046
Pathological fracture at diagnosis
No 1235 426 1.00 n/a 0.783
Yes 160 55 0.96 (0.71e1.29) 0.783
Surgical margins achievedb
Wide/Radical 1200 403 1.00 n/a 0.201
Marginal 182 71 1.11 (0.83e1.49) 0.482
Intralesional 13 7 1.98 (0.91e4.30) 0.083
Histological response
Good (<10% viable tumour) 724 176 1.00 n/a <0.001
Poor (10% viable tumour) 671 305 2.13 (1.76e2.58) <0.001
CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.
a 240 missing values imputed.
b as reported by the pathologist.
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ered to have metastases at diagnosis. In this selected
cohort, the reported 5-year EFS from diagnosis of 28%
compares well to previous results reported from unse-
lected cohorts of patients with any metastases [22] or
patients with only lung metastases [23] but remains un-
acceptably low. However, comparison to historical data
should be made with caution due to the stage shift over
the last decades with more patients recorded with pri-
mary metastatic disease, probably related to refined
imaging techniques. Historically, 10e15% of patients
with osteosarcoma are reported to have primary meta-
static disease, less than the 17% in this selected cohort
excluding patients with deemed non-resectable meta-
static disease at presentation [24]. For patients in CSR at
all sites (a status achieved 3e6 months after diagnosis),
the 5-year EFS and overall survival from biopsy were
64% and 79%, respectively. An important message for
patients is that after successful surgery, nearly 4 out of 5
are alive five years from diagnosis and the risk of relapse
decreases over time.
The model including prognostic factors available at
diagnosis confirmed previously reported results on theimpact of metastases, site and tumour size with the
strongest impact from the presence of metastases at
presentation [10,11,14]. Tumour size is a factor of
prognostic interest and is likely dependent on many
interconnected factors, including the site (which bone)
of the tumour and the size of the patient. Relative
tumour size was missing for 412 of the patients. We
therefore applied a model in which relative tumour size
was imputed if missing, based on data available from all
otherwise-eligible patients in the models.
Telangiectatic pathology is relatively uncommon
among osteosarcoma subtypes [25], here constituting
4.5% of the cases. We observed that the telangiectatic
subtype had a more favourable prognosis than osteo-
blastic osteosarcoma. This has previously been reported
in univariate analyses in a small series of 28 patients [26].
Our findings reflect the strength of large series, such as
EURAMOS, internationally recruiting many patients
which increase the absolute numbers of patients in the
series with very rare subgroups, such as telangiectatic
osteosarcoma.
We report a statistically significant association be-
tween both age and gender on the risk for event. This is
S. Smeland et al. / European Journal of Cancer 109 (2019) 36e5046in accordance with a meta-analysis including 4838 pa-
tients with osteosarcoma in trials and series (not
including EURAMOS-1) in which both age and gender
were associated with survival, with more favourable
outcomes for younger patients and females [16]. For
both age groups (child vs adult) and gender, the re-
ported HRs were very similar to the reported values in
this study. Thus, a conclusion from these two large se-
ries is that there is a significant but modest correlation of
both age and gender on survival in osteosarcoma.
Previous attempts to stratify up-front treatment for
good (small tumour volume) and poor (metastatic or
axial location) prognostic factors have not yet led to
improved outcomes [27,28]. We observed a prognostic
impact of histological subtypes (i.e. telangiectatic, high-
grade surface and unspecified conventional), consistent
with other series but with a different impact from oste-
osarcoma subtypes on prognosis and in series utilising
other chemotherapy regimens [29,30]. Together, the data
suggest biological differences between subtypes; how-
ever, prospective trials to test if up-front therapy should
be directed by subtype are difficult to conduct because
of the rarity of many subtypes.
We performed a prognostic factor analysis adding
treatment-related factors. An eligibility criterion for
recruitment to the EURAMOS-1 was that surgery with
macroscopic clearance was deemed to be possible at all
sites. Histologic response was added to the EFS model
in addition to the factors at diagnosis. The risk of a
subsequent EFS event was more than doubled in pa-
tients with poor response to pre-operative chemo-
therapy. In the COSS report on 1702 consecutive,
unselected patients with osteosarcoma including pa-
tients with tumour of the extremity and trunk and also
patients with metastases at presentation, an HR of 2.4
was reported, similar to the 2.18 in our cohort [10]. Age
and tumour site retained their prognostic impact in this
model, but there was no good evidence of an impact
from gender. Fewer patients were included in this
analysis than in the model with all registered patients
with localised disease, but the HR reductions, for
tumour site (i.e. axial skeleton) and size, probably reflect
the more challenging surgery for these tumours and not
that the poor prognosis reflect a more aggressive
biology.
One limitation of the current report is that it focuses
on patients with resectable disease, set up to facilitate
recruitment to two specific randomisations. It is likely
that those with unresectable disease have a less favour-
able outlook. Another limitation is missing information
on those patients not randomised, which prevented
investigation by treatment actually received. To facili-
tate efforts towards the randomised comparisons and to
anticipate that most patients would be randomised, the
EURAMOS-1 team did not prospectively collect details
of the post-operative phase of treatment, including
surgery for metastatic disease and histological responsefor all these patients. Therefore, there is some selection
bias in the models.
The EURAMOS-1 has already demonstrated that
large international trials are feasible with no impairment
of the quality of care for the patients. Together with the
results from the EURAMOS-1 trial based on the rand-
omised patients, we consider the current MAP regimen
as a standard chemotherapy in high-grade osteosarcoma
in patients aged <40 years, but note that further efforts
are required to drive improvements. With the
EURAMOS-1 protocol, four collaborating study
groups have established a standard for evaluation and
treatment of patients with osteosarcoma and a unique
platform for further studies; the important matter will
be to identify and develop the next appropriate trial.
In conclusion, nearly 4 out of every 5 patients with
non-metastatic osteosarcoma who have all disease
resected are alive five years later, and the risk of relapse
appears to decrease over time. The reported prognostic
factors in this large cohort reinforces the impact of
known prognostic factors and adds information only
achievable from large studies.Role of the funding source
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Appendix Atration cohort’ patients (N Z 1531)dcomplete-case analysis with no
Adjusted HR (95% CI) p-value Overall p-value
1.00 n/a <0.001
2.39 (1.96e2.93) <0.001
1.00 n/a <0.001
1.97 (1.35e2.88) <0.001
1.00 n/a <0.001
1.42 (1.13e1.77) <0.001
1.59 (1.12e2.28) 0.010
1.00 n/a <0.001
0.89 (0.72e1.09) 0.256
0.71 (0.54e0.95) 0.021
0.58 (0.37e0.91) 0.017
1.15 (0.36e3.65) 0.811
0.56 (0.25e1.29) 0.171
1.00 n/a 0.004
1.29 (1.07e1.56) 0.008
1.33 (1.06e1.66) 0.015
1.00 n/a 0.015
1.18 (1.01e1.39) 0.043
1.00 n/a <0.001
1.35 (1.14e1.59) <0.001
(continued on next page)
Appendix Table A1 (continued )
Characteristic N EFS events Adjusted HR (95% CI) p-value Overall p-value
Pathological fracture at diagnosis
No 1343 558 1.00 n/a 0.457
Yes 188 82 1.00 (0.79e1.28) 0.992
Surgical margins achievedc
Wide/Radical 1295 532 1.00 n/a 0.019
Marginal 214 94 1.02 (0.79e1.31) 0.872
Intralesional 22 14 1.41 (0.81e2.46) 0.226
CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.
a includes possible metastases.
b as reported with no imputed data.
c as reported by the pathologist. Note: 336 missing values on relative tumour volume not imputed (as shown in Table 3 in main text, for
comparison).
Appendix Table A2
Cox model for overall survival (timed from diagnostic biopsy) for ‘registration cohort’ patients (N Z 1867).
Characteristic N OS events Adjusted HR (95% CI) p-value Overall p-value
Pulmonary metastases
No metastasesa 1633 368 1.00 n/a <0.001
Metastases 234 110 2.25 (1.80e2.82) <0.001
Other metastases
No metastasesa 1809 444 1.00 n/a <0.001
Metastases 58 34 2.79 (1.92e4.04) <0.001
Site of the tumour
Other limb site 1562 360 1.00 n/a <0.001
Proximal femur/humerus 234 86 1.67 (1.30e2.14) <0.001
Axial skeleton 71 32 1.85 (1.25e2.72) 0.002
WHO classification of sarcoma at diagnosis
Conventional: chondroblastic 300 87 1.00 n/a 0.012
Conventional: osteoblastic 1154 314 0.91 (0.72e1.16) 0.469
Conventional: other 293 57 0.66 (0.47e0.93) 0.016
Telangiectatic 86 14 0.49 (0.28e0.87) 0.015
Small cell 10 4 1.47 (0.53e4.06) 0.457
High-grade surface 24 2 0.28 (0.07e1.14) 0.076
Age
Child 557 123 1.00 n/a 0.044
Adolescent 921 250 1.32 (1.06e1.65) 0.014
Adult 389 105 1.27 (0.97e1.66) 0.081
Gender
Female 761 163 1.00 n/a 0.001
Male 1106 315 1.40 (1.16e1.70) 0.001
Relative tumour volumeb
Small (<1/3 of involved bone) 851 191 1.00 n/a 0.063
Large (1/3 of involved bone) 680 211 1.21 (0.99e1.49) 0.063
Pathological fracture at diagnosis
No 1645 417 1.00 n/a 0.612
Yes 222 61 1.08 (0.81e1.42) 0.612
Surgical margins achievedc
Wide/Radical 1593 394 1.00 n/a 0.036
Marginal 249 70 0.93 (0.69e1.26) 0.652
Intralesional 25 14 2.00 (1.13e3.52) 0.017
CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.
a includes possible metastases.
b 336 missing values imputed.
c as reported by the pathologist.
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Appendix Table A3
Cox model for overall survival (timed from surgery) for ‘M0-CSR’ patients (N Z 1395).
Characteristic N OS events Adjusted HR (95% CI) p-value Overall p-value
Site of the tumour
Other limb site 1175 200 1.00 n/a 0.001
Proximal femur/humerus 166 47 1.76 (1.25e2.48) 0.001
Axial skeleton 54 20 1.74 (1.06e2.85) 0.027
WHO classification of sarcoma at diagnosis
Conventional: chondroblastic 240 59 1.00 n/a 0.141
Conventional: osteoblastic 830 159 0.90 (0.67e1.23) 0.514
Conventional: other 230 37 0.66 (0.43e1.01) 0.054
Telangiectatic 69 9 0.57 (0.27e1.19) 0.136
Small cell 6 2 1.42 (0.34e5.83) 0.629
High-grade surface 20 1 0.18 (0.02e1.28) 0.086
Age
Child 409 59 1.00 n/a 0.041
Adolescent 689 147 1.48 (1.09e2.01) 0.012
Adult 297 61 1.26 (0.87e1.84) 0.217
Gender
Female 586 90 1.00 n/a 0.001
Male 809 177 1.52 (1.18e1.97) 0.001
Relative tumour volumea
Small (<1/3 of the involved bone) 679 116 1.00 n/a 0.185
Large (1/3 of the involved bone) 476 113 1.19 (0.92e1.55) 0.185
Pathological fracture at diagnosis
No 1235 234 1.00 n/a 0.851
Yes 160 33 1.04 (0.70e1.53) 0.851
Surgical margins achievedb
Wide/Radical 1200 218 1.00 n/a 0.073
Marginal 182 43 1.13 (0.77e1.65) 0.533
Intralesional 13 6 2.73 (1.15e6.47) 0.023
Histological response
Good (<10% viable tumour) 724 87 1.00 n/a <0.001
Poor (10% viable tumour) 671 180 2.45 (1.88e3.20) <0.001
CI, confidence interval; EFS, event-free survival; HR, hazard ratio; WHO, World Health Organisation.
a 240 missing values imputed.
b as reported by the pathologist.
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